A Study of LY2886721 in Healthy Participants

Lilly

Status and phase: Completed; Phase 1

Conditions: Healthy Volunteers

Treatments: Drug: Placebo; Drug: LY2886721

Study type: Interventional

Funder types: Industry

Identifiers

NCT01534273

14464

I4O-MC-BACJ (Other Identifier)

Details and patient eligibility

About

The purpose of this phase I study in healthy participants will be to evaluate the safety and tolerability of LY2886721 single and multiple doses, to evaluate how the body handles the drug, and to evaluate the drug's effect on the body.

Enrollment: 30 patients

Sex: All

Ages: 20+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy men and non-childbearing potential women
• Body mass index (BMI) between 18.0 and 32.0 kilograms per square meter (kg/m^2)
• Are reliable and willing to make yourself available for the duration of the study and are willing to follow study procedures and research unit policies

Exclusion criteria

• Taking over-the-counter or prescription medication with the exception of vitamins or minerals
• Smoke more than 10 cigarettes per day
• Drink more than 5 cups of caffeine containing beverages (for example, coffee, tea) per day

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

30 participants in 4 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Single oral dose and/or once daily (QD) oral dosing for 14 consecutive days

Treatment:

Drug: Placebo

35 mg LY2886721

Experimental group

Description:

QD oral dosing for 14 consecutive days

Treatment:

Drug: LY2886721

70 mg LY2886721

Experimental group

Description:

Single oral dose or single oral dose followed by QD oral dosing for 14 consecutive days

Treatment:

Drug: LY2886721

140 mg LY2886721

Experimental group

Description:

Single oral dose

Treatment:

Drug: LY2886721